Rafferty Asset Management’s Akebia Therapeutics AKBA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $924K | Buy |
253,954
+47,324
| +23% | +$172K | ﹤0.01% | 776 |
|
|
2025
Q1 | $397K | Buy |
206,630
+26,878
| +15% | +$51.6K | ﹤0.01% | 911 |
|
|
2024
Q4 | $342K | Buy |
+179,752
| New | +$342K | ﹤0.01% | 998 |
|
|
2022
Q2 | – | Sell |
-702,647
| Closed | -$504K | – | 1127 |
|
|
2022
Q1 | $504K | Sell |
702,647
-35,428
| -5% | -$25.4K | ﹤0.01% | 990 |
|
|
2021
Q4 | $1.67M | Buy |
738,075
+64,136
| +10% | +$145K | 0.01% | 720 |
|
|
2021
Q3 | $1.94M | Buy |
673,939
+78,993
| +13% | +$228K | 0.01% | 643 |
|
|
2021
Q2 | $2.26M | Sell |
594,946
-328,008
| -36% | -$1.24M | 0.01% | 653 |
|
|
2021
Q1 | $3.12M | Buy |
922,954
+628,925
| +214% | +$2.13M | 0.02% | 461 |
|
|
2020
Q4 | $823K | Sell |
294,029
-220,207
| -43% | -$616K | 0.01% | 563 |
|
|
2020
Q3 | $1.29M | Buy |
514,236
+471,362
| +1,099% | +$1.18M | 0.02% | 537 |
|
|
2020
Q2 | $582K | Buy |
+42,874
| New | +$582K | 0.01% | 675 |
|
|
2020
Q1 | – | Sell |
-57,128
| Closed | -$361K | – | 602 |
|
|
2019
Q4 | $361K | Sell |
57,128
-77,688
| -58% | -$491K | 0.01% | 750 |
|
|
2019
Q3 | $528K | Sell |
134,816
-165,115
| -55% | -$647K | 0.01% | 656 |
|
|
2019
Q2 | $1.45M | Buy |
299,931
+174,540
| +139% | +$845K | 0.03% | 493 |
|
|
2019
Q1 | $1.03M | Buy |
+125,391
| New | +$1.03M | 0.02% | 540 |
|